SJSogol Stephanie Javadi

Sogol Stephanie Javadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sogol Stephanie Javadi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medicare Part D Prescription Claims for Brodalumab: Analysis of Annual Trends for 2017-2019

    by Aislyn Oulee, Sogol S Javadi, Grace Sora Ahn, Julia-Tatjana Maul, Jashin J Wu

    To the Editor:Brodalumab, a monoclonal antibody targeting IL-17RA, was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of modera

  • Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review

    by Alexandra Norden, Aislyn Oulee, Leena Munawar, Sogol Stephanie Javadi, George Han, Jashin J. Wu

    Biologics may elicit the production of anti-drug antibodies (ADAs), the clinical significance of which is not fully understood. ADA development in psoriasis patients on IL-17 inhibitors was evaluated by incidence, impact on efficacy, and relationship with adverse events. We systematically searched PubMed, Cochrane, and Embase databases, identifying 456 references. 17 studies met inclusion criteria. ADA incidence was: 0% to 5.5% (secukinumab), 11% to 19.4% (ixekizumab), 0% to 3.3% (brodalumab), and 19% to 39% (bimekizumab). Neutralizing antibody incidence was: 0% to 1.5% (secukinumab), 0% to 3.5% (ixekizumab), and 0% (brodalumab). ADA presence alone with secukinumab, ixekizumab, and bimekizumab did not impact drug efficacy. Brodalumab was the only one of the IL-17 inhibitors, which showed a reduction in efficacy in ADA + patients. In one analysis, high ADA titers to ixekizumab were associated with diminished treatment response. ADAs to secukinumab and bimekizumab were not associated with adverse events. There were limited data on ADAs and safety with ixekizumab or brodalumab. Overall, when monitoring patients on secukinumab, ADAs, titers, and the presence of neutralizing antibodies were not prognostic of outcomes. However, monitoring for ADAs with brodalumab and measuring titers with ixekizumab may be of value clinically.


  • Phototherapy trends in dermatology 2015–2018

    by Aislyn Oulee, Sogol S. Javadi, Amylee Martin, Tran Do, Jashin J. Wu

    Background: Trends in phototherapy utilization including its main clinical indications were last characterized by Luersen et al. for the time period of 1997-2010. In this study, we update data on the use of phototherapy in the United States from 2015-2018. Methods: We queried the National Ambulatory Medical Care Survey (NAMCS) data on number of phototherapy visits as well as demographics and associated dermatoses. Results: There were an approximately 1.31 million outpatient phototherapy visits during the study period with a decreasing trend over time. Leading indications for phototherapy were dermatitis not otherwise specified (NOS), (25.7%) followed by atopic dermatitis (AD) (11.7%), and pruritus (9.7%). Conclusion: There is a downtrend in the use of phototherapy from 2015-2018. Psoriasis is no longer the main indication for phototherapy, which may be due to the advent of highly effective novel biologics.


  • Open Access

    Attitudes and perceptions of next-of-kin/loved ones toward end-of-life HIV cure-related research: A qualitative focus group study in Southern California

    by Sogol S. Javadi, Kushagra Mathur, Susanna Concha-Garcia, Hursch Patel, Kelly E. Perry, Megan Lo, Jeff Taylor, Andy Kaytes, Susan Little, Sara Gianella, et al.

    As end-of-life (EOL) HIV cure-related research expands, understanding perspectives of participants’ next-of-kin (NOK) is critical to maintaining ethical study conduct. We conducted two small focus groups and two one-on-one interviews using focus group guides with the NOK of Last Gift study participants at the University of California, San Diego (UCSD). Participating NOK included six individuals (n= 5 male andn= 1 female), including a grandmother, grandfather, partner, spouse, and two close friends. Researchers double-coded the transcripts manually for overarching themes and sub-themes using an inductive approach. We identified six key themes: 1) NOK had an accurate, positive understanding of the Last Gift clinical study; 2) NOK felt the study was conducted ethically; 3) Perceived benefits for NOK included support navigating the dying/grieving process and personal growth; 4) Perceived drawbacks included increased sadness, emotional stress, conflicted wishes between NOK and study participants, and concerns around potential invasiveness of study procedures at the EOL; 5) NOK expressed pride in loved ones’ altruism; and 6) NOK provided suggestions to improve the Last Gift study, including better communication between staff and themselves. These findings provide a framework for ethical implementation of future EOL HIV cure-related research involving NOK.


  • “My Death Will Not [Be] in Vain”: Testimonials from Last Gift Rapid Research Autopsy Study Participants Living with HIV at the End of Life

    by Kelly E. Perry, Karine Dubé, Susanna Concha-Garcia, Hursch Patel, Andy Kaytes, Jeff Taylor, Sogol Stephanie Javadi, Kushagra Mathur, Megan Lo, Brandon Brown, et al.

    Introduction: End-of-life (EOL) HIV cure-related research provides a novel approach to studying HIV reservoirs. The Last Gift is a rapid autopsy research study at the University of California San Diego, which enrolls terminally-ill people living with HIV (PLWHIV) with a desire to contribute to HIV cure-related research. Methods: We conducted in-depth baseline and follow-up interviews with Last Gift study participants. We analyzed interview data applying conventional content analysis. Results: Since summer 2017, 13 participants have been enrolled (n = 11 males and 2 females; aged 45– 89 years) and 8 participants interviewed. Terminal illnesses included cancers, heart diseases and neurodegenerative illnesses. Our analysis revealed five key themes: 1) The Last Gift study has tremendous meaning for participants at the end of their life. 2) HIV-specific altruism was a primary motivator to join the Last Gift study, nested within the context of community, scientific advancement, and moral obligation. 3) Participants did not expect physical benefits yet they perceived emotional/psychological, financial, and societal/scientific benefits. 4) There were minimal participant-perceived risks and concerns. 5) Last Gift participants expressed immense gratitude toward study staff. Discussion: The Last Gift study provides a framework for ethical HIV cure-related research at EOL and highlighted participants’ perspectives, motivations, and experiences. Knowing how PLWHIV understand and experience such studies will remain critical to designing ethical, fully informed HIV cure research protocols that are acceptable to PLWHIV.


  • Perceptions of Next-of-Kin/Loved Ones About Last Gift Rapid Research Autopsy Study Enrolling People with HIV/AIDS at the End of Life: A Qualitative Interview Study

    by Karine Dubé, Hursch Patel, Susanna Concha-Garcia, Kelly E. Perry, Kushagra Mathur, Sogol Stephanie Javadi, Jeff Taylor, Andy Kaytes, Brandon Brown, John A. Sauceda, et al.

    Introduction: A growing number of people living with HIV/AIDS (PLWHA) are participating in HIV cure-related research at the end of life (EOL). Due to the novelty of EOL HIV cure-related research, there is a need to understand how their next-of-kin (NOK) perceive such research. Methods: We conducted in-depth interviews with NOK of Last Gift study participants at the University of California San Diego (UCSD). The Last Gift study occurs in the context of the EOL and involves a full body donation. NOK completed two interviews: 1) shortly after the participants’ enrollment in the study, and 2) following death. We applied thematic analysis to analyze qualitative data. Results: NOK included 7 individuals (5 males and 2 females), including: two spouses, one ex-partner, one sister, a grand-mother/grand-father, and a close friend. Thematic analysis revealed five key themes: 1) NOK viewed the Last Gift program in a positive light and had an accurate overall understanding of the study; 2) NOK identified factors that motivated participants to donate their body to science; 3) NOK identified benefits of the Last Gift program for both the donors and themselves; 4) NOK did not perceive any physical risks or decisional regrets of study, but wanted to minimize psychosocial impacts and ensure the dignity of participants at all times; and 5) NOK noted elements that remained essential to the successful implementation of EOL HIV cure-related research, such as early involvement and clear communication. Discussion: Our study uniquely contributes to increased understanding and knowledge of what is important from the point of view of supportive NOK to ensure successful implementation of EOL HIV cure-related research. More research will be needed to understand perspectives of less supportive NOK.


  • Open Access

    Altruism: Scoping review of the literature and future directions for HIV cure-related research

    by Karine Dubé, Kelly E. Perry, Kushagra Mathur, Megan Lo, Sogol S. Javadi, Hursch Patel, Susanna Concha-Garcia, Jeff Taylor, Andy Kaytes, Lynda Dee, et al.


  • Differential sensitivity of structural, diffusion, and resting‐state functional MRI for detecting brain alterations and verbal memory impairment in temporal lobe epilepsy

    by Yu‐Hsuan A. Chang, Anisa Marshall, Naeim Bahrami, Kushagra Mathur, Sogol S. Javadi, Anny Reyes, Manu Hegde, Jerry J. Shih, Brianna M. Paul, Donald J. Hagler, et al.

    Objectives: Temporal lobe epilepsy (TLE) is known to affect large‐scale gray and white matter networks, and these network changes likely contribute to the verbal memory impairments observed in many patients. In this study, we investigate multimodal imaging patterns of brain alterations in TLE and evaluate the sensitivity of different imaging measures to verbal memory impairment.Methods: Diffusion tensor imaging (DTI), volumetric magnetic resonance imaging (vMRI), and resting‐state functional MRI (rs‐fMRI) were evaluated in 46 patients with TLE and 33 healthy controls to measure patterns of microstructural, structural, and functional alterations, respectively. These measurements were obtained within the white matter directly beneath neocortex (ie, superficial white matter [SWM]) for DTI and across neocortex for vMRI and rs‐fMRI. The degree to which imaging alterations within left medial temporal lobe/posterior cingulate (LMT/PC) and left lateral temporal regions were associated with verbal memory performance was evaluated.Results: Patients with left TLE and right TLE both demonstrated pronounced microstructural alterations (ie, decreased fractional anisotropy [FA] and increased mean diffusivity [MD]) spanning the entire frontal and temporolimbic SWM, which were highly lateralized to the ipsilateral hemisphere. Conversely, reductions in cortical thickness in vMRI and alterations in the magnitude of the rs‐fMRI response were less pronounced and less lateralized than the microstructural changes. Both stepwise regression and mediation analyses further revealed that FA and MD within SWM in LMT/PC regions were the most robust predictors of verbal memory, and that these associations were independent of left hippocampal volume.Significance: These findings suggest that microstructural loss within the SWM is pronounced in patients with TLE, and injury to the SWM within the LMT/PC region plays a critical role in verbal memory impairment.


  • Open Access

    Ethical considerations for HIV cure-related research at the end of life

    by Karine Dubé, Sara Gianella, Susan Concha-Garcia, Susan J Little, Andy Kaytes, Jeff Taylor, Kushagra Mathur, Sogol Javadi, Anshula Nathan, Hursch Patel, et al.

    The U.S. National Institute of Allergies and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH) have a new research priority: inclusion of terminally ill persons living with HIV (PLWHIV) in HIV cure-related research. For example, the Last Gift is a clinical research study at the University of California San Diego (UCSD) for PLWHIV who have a terminal illness, with a prognosis of less than 6 months. As end-of-life (EOL) HIV cure research is relatively new, the scientific community has a timely opportunity to examine the related ethical challenges. Following an extensive review of the EOL and HIV cure research ethics literature, combined with deliberation from various stakeholders (biomedical researchers, PLWHIV, bioethicists, and socio-behavioral scientists) and our experience with the Last Gift study to date, we outline considerations to ensure that such research with terminally ill PLWHIV remains ethical, focusing on five topics: 1) protecting autonomy through informed consent, 2) avoiding exploitation and fostering altruism, 3) maintaining a favorable benefits/risks balance, 4) safeguarding against vulnerability through patient-participant centeredness, and 5) ensuring the acceptance of next-of-kin/loved ones and community stakeholders. EOL HIV cure-related research can be performed ethically and effectively by anticipating key issues that may arise. While not unique to the fields of EOL or HIV cure-related research, the considerations highlighted can help us support a new research approach. We must honor the lives of PLWHIV whose involvement in research can provide the knowledge needed to achieve the dream of making HIV infection curable.